Recursion
Recursion Pharmaceuticals, commonly referred to as Recursion, is a pioneering biotechnology company headquartered in the United States. Founded in 2013, Recursion has rapidly established itself at the forefront of drug discovery and development, leveraging advanced machine learning and high-throughput biology to transform the way diseases are treated. With a strong operational presence in major regions across the US, Recursion focuses on utilising its unique platform to identify novel therapeutics for a range of conditions, particularly in rare diseases and oncology. The company’s innovative approach combines vast biological data with cutting-edge technology, setting it apart in the competitive biotech landscape. Notable achievements include significant partnerships and collaborations that enhance its market position, underscoring Recursion's commitment to revolutionising healthcare through data-driven insights and transformative therapies.
DitchCarbon Score
How does Recursion's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recursion's score of 24 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Recursion's reported carbon emissions
In 2022, Recursion Pharmaceuticals, headquartered in the US, reported total carbon emissions of approximately 1,249,580 kg CO2e, comprising 269,260 kg CO2e from Scope 1 and 980,320 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Recursion has not set specific reduction targets or initiatives as indicated by the absence of SBTi reduction targets or documented climate pledges. The emissions data is not cascaded from a parent company, and all figures are directly reported by Recursion Pharmaceuticals, Inc. The company’s commitment to addressing climate change remains unclear, as no significant reduction initiatives or targets have been established.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 269,260 |
| Scope 2 | 980,320 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recursion is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
